Core Viewpoint - A senior executive from Novo Nordisk characterized the ongoing trial of its obesity medication for Alzheimer's treatment as a "lottery ticket" due to the uncertainty surrounding the results [1] Group 1 - The trial is focused on repurposing a successful obesity drug for a new indication, which reflects the company's innovative approach in drug development [1] - The executive's comments highlight the speculative nature of the trial, indicating that while there is potential, the outcome remains unpredictable [1] - The characterization of the trial as a "lottery ticket" suggests that the company is aware of the high risks involved in this venture [1]